The development of autoimmune disease is accompanied by the acquired recognition of new self-determinants, a process commonly referred to as determinant spreading. In this study, we addressed the question of whether determinant spreading is pathogenic for progression of chronic-relapsing experimental autoimmune encephalomyelitis (EAE), a disease with many similarities to multiple sclerosis (MS). Our approach involved a systematic epitope mapping of responses to myelin proteolipid protein (PLP) as well as assaying responses to known encephalitogenic determinants of myelin basic protein (MBP 87-99) and myelin oligodendrocyte g|yco-protein (MOG 92-106) at various times after induction of EAE in (SWRXSJL)F1 mice immunized with PLP 139-151. We found that the order in which new determinants are recognized during the course of disease follows a predictable sequential pattem. At monthly intervals after immunization with p139-151, responses to PLP 249-273, MBP 87-99, and PLP 173-198 were sequentially accumulated in all mice examined. Three lines of evidence showed that determinant spreading is pathogenic for disease progression: (a) spreading determinants mediate passive transfer of acute EAE in naive (S'W~• 1 recipients; (b) an invariant relationship exists between the development of relapse/progression and the spreading of recognition to new immunodominant encephalitogenic determinants; and (c) after EAE onset, the induction ofpeptidespecific tolerance to spreading but not to nonspreading encephalitogenic determinants prevents subsequent progression of EAE. Thus, the predictability of acquired self-determinant recognition provides a basis for sequential determinant-specific therapeutic intervention after onset of the autoimmune disease process.
Summary
The development of autoimmune disease is accompanied by the acquired recognition of new self-determinants, a process commonly referred to as determinant spreading. In this study, we addressed the question of whether determinant spreading is pathogenic for progression of chronic-relapsing experimental autoimmune encephalomyelitis (EAE), a disease with many similarities to multiple sclerosis (MS). Our approach involved a systematic epitope mapping of responses to myelin proteolipid protein (PLP) as well as assaying responses to known encephalitogenic determinants of myelin basic protein (MBP 87-99) and myelin oligodendrocyte g|yco-protein (MOG 92-106) at various times after induction of EAE in (SWRXSJL)F1 mice immunized with PLP 139-151. We found that the order in which new determinants are recognized during the course of disease follows a predictable sequential pattem. At monthly intervals after immunization with p139-151, responses to PLP 249-273, MBP 87-99, and PLP 173-198 were sequentially accumulated in all mice examined. Three lines of evidence showed that determinant spreading is pathogenic for disease progression: (a) spreading determinants mediate passive transfer of acute EAE in naive (S'W~• 1 recipients; (b) an invariant relationship exists between the development of relapse/progression and the spreading of recognition to new immunodominant encephalitogenic determinants; and (c) after EAE onset, the induction ofpeptidespecific tolerance to spreading but not to nonspreading encephalitogenic determinants prevents subsequent progression of EAE. Thus, the predictability of acquired self-determinant recognition provides a basis for sequential determinant-specific therapeutic intervention after onset of the autoimmune disease process. E xperimental autoimmune encephalomyelitis (EAE) 1 is an animal model commonly used in multiple sclerosis (MS) research. EAE is induced by immunization of animals with myelin proteins, and clinical disease develops when primed CD4 + T cells enter the central nervous system (CNS) and recognize encephalitogenic peptide determinants presented in the context of class II MHC molecules. Perivascular inflammation often leads to clinical paralysis and demyelination. In SjL/j, swR/j, and (SWRXSJL)F1 mice, recovery from the primary attack is followed by a relapsing-remitting pattern of disease with a subsequent chronic progression of disability reminiscent of MS. How1Abbreviations used in this paper: CNS, cental nervous system; DTH, delayed-type hypersensitivity; EAE, experimental autoimmune encephalomyelitis; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; PLP, proteolipid protein.
ever, the underlying cause for relapse and chronicity in both MS and EAE are presently unclear.
Recent studies have suggested that acquired recognition of new self-determinants, a process commonly referred to as determinant spreading, may be implicated in relapse and disease progression. McCarron et al. (1) showed that during relapse, (SJL• 1 (H-2 s,u) mice acquire a new class II MHC-restricted response to myelin basic protein (MBP) that was not apparent during the primary inflammatory attack. Clayton et al. (2) found that B10.PL (H-2 u) mice made neonatally tolerant to the immunodominant IA urestricted pl-9 determinant of MBP remain susceptible to disease induction with intact MBP containing a nondominant IEU-restricted second determinant, p35-47. Furthermore, Lehmann et al. (3) showed that immunoreactivity to the nondominant determinants MBP 35-47, (6) inhibited the progression ofpl39-151-induced EAE by inducing tolerance to whole PLP after recovery from the primary attack. These data suggest that spreading to new PLP determinants may provide a basis for peptide-specific therapy after disease onset.
In this study, we have extended these earlier findings by systematically assessing the pattern ofintra-and intermolecular determinant spreading as a function of time in (SWR• mice immunized with the immunodominant PLP 139-151 encephalitogen. We report that the order in which new determinants are recognized during the course of disease follows an ordered, predictable, sequential pattern. Moreover, an invariant relationship exists between the development of relapse/progression and spreading of recognition to new immunodominant encephalitogenic determinants. Finally, we show that peptide-specific treatment with the primary spreading determinant after disease onset prevents subsequent chronic progression ofEAE. These data support the view that determinant spreading is a pathogenic process that leads to relapse and chronic progression of autoimmune disease, and that the predictable sequential pattern of spreading provides the basis for peptide-specific therapy after the onset of clinical disease.
Materials and Methods
Mice. Female (SWR.XSJL)F1 (H-2 q's) mice were bred at the Research Institute of the Cleveland Clinic Foundation by mating SW1L/J (H-2q) females with SJL/J (H-2 s) males purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were immunized at 7-12 wk of age. All protocols for animal research met with prior approval of the Animal Research Committee of the Cleveland Clinic Foundation in compliance with the Public Health Service policy on humane care and use of laboratory animals.
Bulk Peptide Synthesis. The PLP peptides 104-117 KTTIC-GKGLSATVT, 139-151 HSLGKWLGHPDKF (serine for cysteine at residue 140), 178-191 NTWTTCQSIAFPSK, and 258-273 IAA-TYNFAVLKLMGR.G as well as MBP 87-99 VHFFKNIVTPRTP and MOG 92-106 DEGGYTCFFRDHSYQ were either purchased commercially (Bio-Synthesis, Lewisville, TX) or were synthesized manually as previously described (7) with standard solid-phase methodology using side chain-protected t-Boc amino acids (Peninsula Laboratories Inc., Belmont, CA). All peptides were purified >90% by reverse-phase HPLC using a 22 • 250-ram C-18 column (Vydac Separations Group, Hesperia, CA). The identity of purified peptides was confirmed by amino acid analysis.
Active EAE Induction. EAE was induced as previously described (7) . (SWR• mice were immunized by subcutaneous injection in the abdominal flanks on day 0 with 100 nm of PLP 139-151 peptide (154 b~g) and 400 ~g Mycobacterium tuberculosis H37RA (Difco Laboratories Inc., Detroit, MI) in 200 Ixl of an emulsion of equal volumes of water and IFA (Difco Laboratories Inc.). On days 0 and 3, each mouse also received 0.6 X l0 t(} i.v. Bordetella pertussis bacilli (Michigan Department of Public Health, Lansing, MI). In this study, all mice developed clinical EAE within 30 d after immunization.
Clinical and Histologic Evaluation. All mice were weighed and examined daily for neurologic signs as previously described (7) according to the following criteria: 0, no disease; l, decreased tail tone or slightly clumsy gait; 2, tail atony and/or moderately clumsy gait and/or poor righting ability; 3, limb weakness; 4, limb paralysis; 5, moribund state. The presence of relapse was determined when mice showed an increase in observed neurologic disability of at least one clinical score unit. The increased neurologic deficit was typically accompanied by an abrupt and substantial (~7%) weight loss. Brains and spinal cords were fixed in 10% phosphatebuffered formalin, and paraffin-embedded sections were stained with luxol fast blue and counterstained with hematoxylin and eosin. The presence of inflammatory loci, cellular infdtrates, and demyelination in CNS meninges and parenchyma was determined under light microscopy.
PLP Pin Peptides. A PLP pin peptide series (see Fig. 1 ) effectively representing a walkthrough of the entire 276-amino acid primary sequence of mouse PLP (8, 9) was purchased from Chiron Mimotopes (San Diego, CA). A total of 265 overlapping 12-mers were synthesized on high density polyethylene rod tips assembled into holders designed in 96-well microtiter plate format (10) . When Fmoc biochemistry is used in the synthesis, cleavage of one peptide per microtiter well can occur (11, 12) . Similar pin series have been used successfully to map T cell determinants of hen egg white lysozyme (12) , MBP (3, 13) , and glutamic acid decarboxylase (14) . Upon arrival, 1 txg of each PLP pin peptide was dissolved in 500 6xl of a solution of 40% acetonitrile (Aldrich Chemical Co., Milwaukee, WI) in 10 mM Hepes buffer (GIBCO BRL, Gaithersburg, MD). Working aqueous concentrations of pin peptides were prepared at 150 txg/ml in PBS, pH 7. Determinant Spreading during EAE. At days 7, 28, 56, and 84 after immunization of (SWR • SJL) F1 mice with p 139-151, spleen cells were tested for proliferative responses to the 265 overlapping PLP pin peptides, to MBP 87-99, an immunodominant encephalitogenic determinant for both SJL/J (15, 16) and SWtL/J (17) mice, and to myelin oligodendrocyte glycoprotein (MOG) 92-106, an immunodominant encephalitogen for SjL/j mice (18) . Mononuclear cells were separated from single-cell suspensions by centrifugation on Lympholyte-M (Accurate Chemical & Science Corp., Westbury, NY) for 20 rain at 2,500 rpm. Cells collected from the interface were washed three times in HBSS (GIBCO BRL) and resuspended in serum-free HL-1 media (Hycor, Irvine, CA) supplemented with 2 mM fresh r-glutamine, 100 U/ml penicillin, 100 ~g/ml streptomycin, and 30 mM Hepes buffer (GIBCO BILL). Each well contained 2 • 105 spleen cells with 15 Ixg/ml pin peptide in a total volume of 200 Ixl. Triplicate wells containing 15 txg/ml MBP 87-99 and MOG 92-106 were also tested. Triplicate positive control wells contained anti-mouse CD3 antibody at 10 I~g/ml (PharMingen, San Diego, CA) or 20 txg/rnl M. tuberculosis H37RA (Difco Laboratories Inc.), whereas negative control wells contained either no peptide or 1 of 30 irrelevant pin peptides of myohemerythrin, a protein having minimal sequence homology with myelin proteins (19) . Dose responses to whole PLP (0.1-100 Ixg/ml) were also assessed in each experiment. The PLP was prepared from a washed total lipid ex-
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The Determinant Spreading Cascade in Autoimmune Encephalomyelitis tract of bovine white matter (20) and was purified and converted to aqueous form as previously described (7) . Cultures were incubated at 37~ in humidified air containing 5% CO 2. At 4 d, cultures were pulsed with [methyl-3H]thymidine (1.0 p~Ci/well, sp act 6.7 Ci/mmol; New England Nuclear, Boston,/VIA), and the cells were harvested after 16 h by aspiration onto glass fiber filters. Levels of incorporated radioactivity were determined by scintillation spectrometry. Test wells containing 15 p,g/ml of peptide were considered positive when their stimulation index was at least two times both the SD and the mean proliferation of control wells without peptide. Identification of PLP antigenic determinants required that positive proliferative responses be generated by at least three adjacent overlapping 12-mers. Responses to irrelevant myohemerythrin peptides were never observed, and responses to PLP peptides did not occur in naive mice or in control mice immunized with BSA. Responses to whole PLP were inconsistent between and within different preparations and often did not accompany marked responses to immunodominant PLP determinants.
T Cell Lines and T Cell Assays.
To determine the activation profile of the novel spreading determinant PLP 258-273, short-term (SWR• T cell lines were generated to the immunodominant p139-151 and to the nonencephalitogenic p258-273 as previously described (21) . LN cells from day 10 peptide-primed mice were cultured at 2.5 X 106 cells/ml in 24-well flat-bottomed plates (Falcon Labware, Becton Dickinson & Co.) in a total volume of 2.0 ml/well of DMEM (GIBCO BILL) supplemented with 10% fetal bovine serum (Hyclone Laboratories Inc., Logan, UT), 2 mM fresh L-glutamine, 100 U/ml penicillin, 100 p~g/ml streptomycin, 30 ELISAs. Purified anti-mouse cytokine capture/detection antibody pairs were purchased from PharMingen. The capture/ detection antibody pairs used in this study included anti-mouse IFN-~/ (R4-6A2 and biotin-XMG1.2), anti-mouse IL-2 (JES6-1A12 and biotin-JES6-5H4), anti-mouse IL-4 (BVD4-1Dll and biotin-BVD6-24G2), and anti-mouse IL-10 (JES5-2A5 and biotin-SXC-1). 50 p,1 of coating buffer (0.1 M NaHCO3, pH 8.2) containing capture antibody at 4 p~g/ml was added to each microtiter well in 96-well enhanced protein binding ELISA plates (Coming Glass Inc., Coming, NY). After overnight incubation at 4~ plates were washed with PBS/Tween (0.5%) and blocked by adding 200 p,1/well of PBS containing 3% BSA. Plates were incubated for 2 h at room temperature and washed. 100 g,1 of recombinant cytokine standards (PharMingen) at multiple concentrations and 100 g,1 of each test sample were added to duplicate wells. After incubation for 4 h at room temperature and washing, 100 p~l of appropriate detection antibody at 2 p~g/ml was added to duplicate wells for 45 rain at room temperature. After washing, 100 p,1 of a 1:400 dilution ofavidin peroxidase (Sigma Chemical Co., St. Louis, MO) was added to each well and incubated for 30 rain at room temperature. Plates were washed, and each well received 100 p~l of fresh substrate buffer containing 300 p,g/ml of the substrate 2,2"-azino-bis(3-ethylbenzthiazollne-6-sulfonic acid) (ABTS; Sigma Chemical Co.) and 0.03% H202 in 0.1 M citric acid at pH 4.35. After 12 rain, the absorbance at 405 nm was measured using an ELISA microplate autoreader (Bio-Tek Instruments, Inc., Winooski, VT). Standard values were plotted as absorbance (optical density) vs cytokine concentration, and sample cytokine concentrations were determined as values within the linear part of the standard curve.
Passive Transfer of EAE with Spreading Determinants. 50 Hemisplenectomy. 28 d after immunization with p139-151, (SWR• mice were anesthetized by subcutaneous injection of 200 p,g/kg ketamine (Fort Dodge Laboratories, Fort Dodge, IA) and 10 ~g/kg xylazine (Miles Laboratories, Shawnee Mission, KS), and an incision was made in the shaved left abdominal flank under sterile conditions. Half of the spleen was removed for immunologic testing using a battery operated cauterizer 0orgensen Laboratories, Loveland, CO), which kept bleeding to a minimum. Care was taken to avoid obstruction to blood flow through the splenic artery and vein. The abdominal wall was closed with 4.0 silk suture, and the skin was closed with wound clips. Hemisplenectonfized mice were weighed and examined daily for neurologic signs and were killed on day 84 for retesting autoreactive immune responses using the remaining half of the spleen.
Induction of Peptide-specific Tolerance. 10 d after onset of EAE, (SWR• mice were tolerized to either PLP 104-117 or MBP 87-99 by one of two methods: (a) tail vein injection of 300 p,g of peptide in 0.2 ml PBS according to previously described procedures (22, 23) ; or (b) intraperitoneal injection of 100 p,g peptide in 0.2 ml of an emulsion containing equal volumes of aqueous peptide and IFA. The latter method has been described previously (2, 24) and has been recendy shown in adult mice to induce a splenic CD4 + Th2 Ag-specific response involving the production of IL-5 and IL-10 (25). All mice were subsequently weighed and evaluated daffy by an investigator blinded to the tolerance protocols.
Delayed-type Hypersensitivity (DTH) Ear Swelling. Determinantspecific DTH reactions were quantitated as previously described (26 Figure 1 . Epitope-mapping pin peptide series for PLP. An overlapping series of 12-mer peptides effectively representing a walkthrough of the entire 276 amino acid primary sequence of mouse PLP was used to measure determinant spreading during the course of EAE in (SWR• 1 mice. In addition, dose-response profiles were also determined for reactivity to the SjL/j encephalitogenic determinants MBP 87-99 and MOG 92-106.
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Responses to the priming determinant p139-151 were readily apparent in all mice on all days tested and were often characterized by plasticity of determinant recognition involving reactivity to peptide regions directly adjacent to the defined p139-151 immunogen (Table 1) . On day 7, two of three mice responded to PLP 152-174, a region directly adjacent to the COOH-terminus ofp139-151, whereas on day 84 two of three mice responded to a peptide region flanking the NH2-terminus ofp139-151.
Clinical (Table 1 ). In addition, one mouse responded to PLP 47-60 ETYFSKN-YQDYEYL on day 56. The failure to observe reactivity to this determinant before or at any other time thereafter suggests that such ephemeral determinant recognition may reflect aborted autoreactivity. A response to MOG 92-106 was observed in one mouse on day 84 only. Plasticity of recognition was also apparent in reactivity to spreading determinants, particularly in response to flanking regions of the defined p178-191 encephalitogen (27) on day 84. Thus, broad regional recognition of core and flanking determinants appears to be a characteristic of early self-recognition events initiated by exogenous priming or endogenous spreading. The combined results ofintra-and intermolecular determinant spreading are summarized in Table 2 .
PLP 249-273 Is a Nonencephalitogenic Determinant Involved in Spreading.
The observed autoreactivity to p249-273 was novel and was further examined. PLP 258-273 IAATYN-FAVLKLMGP-,G was synthesized and used as an immunogen in (SWR• mice. Despite extensive efforts, we were unable to induce histologic or clinical EAE by either active immunization or passive transfer with p258-273-primed T cells (data not shown). A similar observation regarding an overlapping PLP sequence was made by Greet et al. (28) in the parental SJL/J strain.
The failure to observe p258-273-mediated disease may be due to inherent activation defects since primed LNC activated by p258-273 showed deficient production of inflammatory Thl cytokines when compared with production by p139-151-activated primed LNC (Fig. 2 A) . Responses to p258-273 were restricted by both MHCq and MHC s, and proliferation ofp258-273-pfimed (SWR• 1 T cell hnes with (SWRXSJL)F1 APC appeared to comprise the additive responses of cultures containing splenic APC from parental SWR/J (H-2q) and SJL/J (H-2 s) mice (Fig. 2  B) . Thus, p258-273 appears to be a nondominant, nonencephalitogenic promiscuous determinant of PLP consistendy involved in determinant spreading but incapable by itself of generating a pathogenic level of Thl inflammatory cytokines.
Passive Transfer of EAE with Spreading Determinants. To de-
termine the pathogenicity of consistent intermolecular spreading to MBP 87-99, the ability to transfer EAE into naive recipients was evaluated. 50 
d after immunization of
The Determinant Spreading Cascade in Autoimmune Encephalomyelitis Table 1 . *Data show the results of three independently performed experiments in which spleens were removed from one mouse on days 7, 28, 56, and 84 after p139-151 immunization and tested for proliferative responses to a pin series of PLP peptides. Test wells containing 15 l.Lg/mi of one pin 12-mer PLP peptide were considered positive when their stimulation index was at least two times both the SD and the mean proliferation of control wells without peptide.
PLP Intramolecular Determinant Spreading in (SWR• 1 Mice* after Immunizations with p139-151~
The criteria for identifying antigenic determinants of PLP required that positive prohferative responses be generated by at least three adjacent 12-mers.
;tData show splenocyte proliferation on days after immunization, not days after EAE onset. All (SWR• SJL)F 1 mice tested from day 28 onward had already developed EAE when tested and did so within 30 d after immunization.
The priming p 139-151 immunogen is underlined throughout. To monitor the development of intermolecular determinant spreading, triphcate wells were tested for responses to 15 ~g/mi MBP 87-99, an immunodominant determinant for both SJL/J and SWR/J parental mouse strains, and MOG 92-106, immunodominant for SJL/J mice. An ephemeral response to PLP 47-60 occurred in one mouse at day 56 only, and a response to MOG 92-106 occurred in one mouse at day 84. All mice from day 56 onward consistently responded to MBP 87-99 (Table 2 ). Significant variations in response to anti-CD3 antibody were not observed, but dose responses to whole PLP were inconsistent and frequently did not coincide with the observed reactivity to immunodominant PLP peptides. (Table 3 ). The severity of disease and time of onset were comparable in both groups of mice and demonstrated the pathogenic rather than protective nature of determinant spreading to the immunodominant MBP 87-99. responses to PLP pin peptides, MBP 87-99, and MOG 92-106 were assessed at two time points within the same mouse. Mice were hemisplenectomized for immune testing 28 d after p139-151 immunization. After recovery from surgery, the mice were weighed and evaluated daily for neurologic impairment, and at day 84 the remaining half of each spleen was retested for responses to all peptides. Five of eight mice developed at least one clinical relapse and showed progression of clinical disease (Table 4) . Moreover, all five relapsing-progressive mice showed a determinant spreading pattern virtually identical to that described for nonsurgically treated mice (Table 2 ). In contrast, the three mice that did not develop clinical relapse and progression also failed to show spreading of recognition to the dominant encephalitogenic peptides MBP 87-99 and PLP 173-198. Thus, it appears that an invariant relationship exists between clinical relapse/progression and spreading of selfrecognition to new immunodominant encephalitogenic determinants.
Invariant Relationship between EAE Relapse~Progression and

Prevention of EAE Progression by Peptide-specific Inhibition of
Determinant Spreading. The predictable sequential spreading pattern in (SWRXSJL)F 1 mice offered an opportunity for directly addressing the pathogenicity of determinant spreading. 10 d after onset of EAE, mice were tolerized by intravenous injection with either the primary spreading determinant MBP 87-99 or with PLP 104-117, an equally potent encephalitogenic determinant for (SWRXSJL)F1 mice (21, 29) not involved in the observed spreading pattern. The results obtained by blinded evaluation indicate that mice tolerized to the spreading MBP 87-99 determinant showed consistent improvement in mean clinical score and delayed progression of clinical disease, whereas mice tolerized to the non-spreading PLP 104-117 determinant continued their progression to disability (Fig. 3 A) . The clinical improvement of MBP 87-99 tolerized mice was accompanied by a corresponding significant inhibition (P --0.0414) of MBP 87-99 DTH as measured by determinant-specific ear swelling (Fig. 3 B) . The inhibition of DTH was antigen specific to the extent that no differences
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The Determinant Spreading Cascade in Autoimmune Encephalomyelitis In addition tO intravenous injection o f peptide, ( S W R .
• SJL)F 1 mice w e r e tolerized 7 d after E A E onset by intraperitoneal i m m u n i z a t i o n in an IFA emulsion containing either the spreading M B P 87-99 determinant, the n o nspreading control encephalitogen PLP 104-117, or IFA emulsion alone. Induction o f M B P 87-99 tolerance after E A E onset resulted in a marked therapeutic effect (Fig. 4  A) . By day 32, a significant i m p r o v e m e n t in m e a n clinical score was evident in mice tolerized to M B P 87-99 c o mpared with sham-(P = 0.0105) or PLP 104-117-tolerized (P = 0.0204) mice. N o significant differences were apparent b e t w e e n PLP 1 0 4 -1 1 7 -and sham-tolerized mice. T h e clinical i m p r o v e m e n t in M B P 8 7 -9 9 -t o l e r i z e d mice was accompanied by a significant inhibition (P = 0.0035) in splenocyte proliferative responses to M B P 87-99, but not to the p139-151 priming determinant (Fig. 4 B) .
Histopathology in Peptide-tolerized EAE Mice. At 3 2 -3 5 d after E A E onset, peptide-tolerized (SWR.XSJL)F 1 mice were killed, and the brains and spinal cords w e r e e x a m i n e d for the appearance o f inflammatory infiltrates and demyelination. M i c e tolerized to the spreading M B P 87-99 determinant consistently s h o w e d inflammatory changes that were qualitatively less severe than those observed in mice tolerized to the nonspreading PLP 104-117 encephalitogen. M B P 8 7 -9 9 -t o l e r i z e d mice had fewer C N S inflammatory infiltrates and markedly less severe demyelination c o mpared w i t h mice tolerized to PLP 104-117 (Fig. 5) . However, no differences were apparent between both groups ofpeptidetolerized mice in their splenocyte proliferative responses to the priming PLP 139-151 irrtmunogen. It is worth noting that intermolecular spreading to MBP 87-99 resulted in a level of autoreactivity on a par with that directed against the priming p139-151 determinant as indicated by the ability to mediate passive transfer of EAE (Table 3) and DTH ( Fig. 3 /3) . Moreover, splenocyte proliferative responses to MBP 87-99 were actually greater than those directed against p 139-151.
Discussion
This study shows that determinant spreading during the development o f autoinmlune disease is an ordered physiologic process in which defined self-determinants are recognized in a sequential predictable manner. Moreover, the mediation o f passively transferred EAE with spreading determinants, the invariant relationship between spreading and chronicity, and the therapeutic effect on disease progression after determinant-specific inhibition of spreading establishes an essential pathogenic role of determinant spreading in the progression of autoimmunity and provides a foundation for therapeutic intervention o f ongoing disease.
Although the detailed mechanisms responsible for exacerbation o f autoimmune demyelinating disease are presently unclear, numerous studies have implicated bursts o f T cell-inflammatory cytokine activity before or during early stages of relapse. Increased IFN-~ and TNF-ot activity (30) and increased TNF-ct and TNF-[3 m R N A levels (31) occur in PBL of MS patients before both clinical relapse and active magnetic resonance scans (31) . Relapse in MS has also been associated with decreased expression o f the antiinflammatory cytokines TGF-[3 and IL-10 in MS (31) . Similarly, inflammatory cytokines have been demonstrated in the CNS during active EAE (32) (33) (34) , whereas recovery has been associated with concomitant decreased CNS expression of IFN-% IL-2, IL-4, and IL-6 and increased expression of IL-10 m R N A (35) . Furthermore, bursts of m R N A expression for inflammatory chemokines occur immediately before the initiation of both EAE onset (36, 37) and relapse (38) in SjL/j mice, whereas abrupt decreased expression often occurs during remission. However, perhaps the most convincing evidence to date for immune mediation of relapse are the results obtained from an IFN-~/clinical trial that produced a high enough rate of MS relapse to terminate treatment (39) .
The results o f this study indicate that the inflammatory cytokine and chemokine activity associated with relapse and chronicity ofautoimmune demyelination are due at least in part to spreading of T h l recognition to new myelin selfdeterminants. However, numerous reports have associated failure to relapse with innate immunoregnlatory mechanisms that appear to target immunogen-primed autoreactive T cells. Apoptosis (40, 41) , CD4 § anti-TCR inhibitory cells (42) (43) (44) , and perhaps CD8 + cells (45, 46) have been implicated in downregulation of the response to the priming immunogen and may explain the nonrelapsing nature o f EAE in Lewis rats and in PL/J and B10.PL mice.
Conversely, such inhibitory mechanisms may be deficient in relapsing and chronic progressive EAE models, thus predisposing to a sustained pathogenic response to the priming immunogen with subsequent transfer o f autoreactivity to spreading determinants. Furthermore, it is conceivable that patients with single demyelinating episodes (e.g., optic neuritis) have intact immunoregulatory mechanisms that result in aborted autoreactivity, whereas patients that develop MS fail to down-regulate their initial self-reactivity and progress by spreading the response to new self-determinants. From this perspective, chronic progression of autoimmune demyelinating disease would appear to require that a threshold inflammatory response to the priming immunogen be maintained long enougl~ to allow the transfer of autoimmune targeting to new determinants. Autoreactivity would be perpetuated by serial transfer o f recognition through a determinant-spreading cascade. In this context, it is worth noting that spreading to the nondominant p249-273 occurs by day 28, coinciding with or immediately following EAE onset. This suggests that p249-273 may repre-
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The Determinant Spreading Cascade in Autoimmune Encephalomyelitis sent an "enhancer" determinant, incapable of mediating EAE induction by itself but capable of amplifying and sustaining the early inflammatory response directed initially against the priming p139-151 immunogen. This type of determinant-mediated inflammatory enhancement may thereby assist in spreading the response to the immunodominant MBP 87-99, a determinant completely capable of mediating and maintaining pathogenicity.
The order in which determinants are recognized during spreading does not follow the traditional immunodominant---)nondominant hierarchy, nor does it favor in any sense an intramolecular bias. Spreading to PLP 249-273, a nondominant determinant according to traditional criteria, occurs before broadening of the response to the immunodominant peptides MBP 87-99 and PLP 173-198. Thus, the dominant recognition of p249-273 during the flow of autoimmune determinant spreading stands in direct conflict with its nondominant character as traditionally defined. However, traditional criteria for defining dominant/nondominant antigenic peptides are based on relative responses to exogenous proteins such as hen egg-white lysozyme (47) (48) (49) . It is not surprising, therefore, that self-determinants having native antigen depots are not recognized during the development of autoimmune disease according to criteria obtained from exogenous immunizations. In essence, spreading flows from one determinant to another based on internal recognition patterns that appear to reflect factors not involved in the recognition of non-self proteins, such as processing and determinant availability within the target organ. Thus, the order in which determinants are 1785
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recognized during the development of autoimmunity reflects an innate spreading dominance based on an immunologic bias that appears to be independent of traditional dominant/nondominant criteria.
Responses to the epitope-mapping PLP peptide series reveals an extraordinary plasticity inherent in immune recognition of autoreactive proteins. At least four components constitute the observed plasticity of self-recognition: (a) recognition of broad protein regions incorporating core and flanking sequences of encephalitogenic determinants; this pattern is typically characteristic of early self-recognition events initiated by either exogenous priming or endogenous spreading (Table 1) ; (b) focusing of recognition to core sequences within each protein region; (c) shifting of epitope responses within each region; and (d) spreading of the response to new regions incorporating new encephalitogenic core determinants. In addition, the development of ephemeral aborted responses (e.g., the response to PLP 47-60 in one mouse on day 56 only) further adds to the inherent supple features of self-recognition.
It appears that immunization with a discrete peptide determinant is sufficient to consistently induce a response to a sequence adjacent to the priming determinant in the native protein but not involved in the initial immunization. This implies that immune recognition of adjacent self-determinants is cognate and that an innate relationship exists between recognition of core determinants and recognition of their adjacent flanking sequences. The nature of such relationships may reflect protein sequence motifs requiring structural or functional complementary ligands, as has been suggested (50) (51) (52) . The ephemeral and shifting nature of flanking region recognition is also of interest and may represent aborted autoimmunity that fails to develop pathogenic consequences. Nevertheless, the plasticity of the observed recognition patterns indicates that autoimmune disease involves self-recognition events characterized by a supple dynamic developmental immune agenda. This dynamic paradigna provides a rationale for therapeutic intervention at each predictable stage in the development ofautoimmunity.
Recent chnical improvements have enabled the identification of patients with single episodes of idiopathic monosymptomatic demyehnating syndromes at high risk for progressing to definite MS (53) . Our preliminary results indicate that such patients have a high rate of self-recognition plasticity and show patterns of reactivity remarkably similar to those described in this study. Such shifting patterns of selfrecognition may be responsible for the observed changes in T cell repertoire restriction occurring in patients with optic neuritis who ultimately develop MS (54) . The coaccumulation of neurologic deficit and promiscuous self-determinant recognition implies that early treatment of autoimmune demyehnating disease would be most desirable. To this end, the predictable and sequential nature of self-recognition plasticity may serve both to target and to monitor the effectiveness of therapeutic strategies used for early treatment of MS and related CNS inflammatory abnormalities.
